Release time：2023-10-12
On December 16, 2021, Zhang Ruikun, investment partner of Hankang Capital, Yang Xiaobing of the Department of Biology and Medicine of Jiangsu Institute of Industry and Research, and their entourage visited the company for exchanges, and Chairman Guan Guoliang and General Manager Chen Qiaoling attended the symposium
Chairman Guan Guoliang welcomed the visit of investment partners Zhang Ruikun and Director Yang, introduced in detail the company's two core technologies: LAMP-IDE rapid gene screening technology and personalized epilepsy treatment management platform technology, and conducted in-depth discussions and exchanges with investors and Director Yang on technical background, technology innovation points, application prospects after productization and social and economic benefits.
General Manager Chen Qiaoling introduced the company's overall operation and the company's recent product planning in medical direction, clinical rapid testing products and food safety testing quick screening products, and showed the company's latest technical achievements to investors.
Investment partner Zhang Ruikun said that Hancom Capital is rooted in the Chinese market and is a venture capital fund focusing on the biomedical industry, committed to investing in biomedicine, diagnostic reagents, and medical devices. Through today's visit, she highly recognized the innovation and broad market prospects of the company's technology, and expressed her hope to cooperate with the company after productization.
